Novavax Inc. NVAX, -2.07% released more extensive data on its Phase 1 trial of a vaccine for COVID-19 Wednesday, and shares rose about 4% in after-hours trading. Novavax previously released findings from the study that said the vaccine candidate induced immune responses and was well-tolerated, but more more data from the study was published Wednesday in The New England Journal of Medicine. "The rapid publication of Phase 1 results from our trial in a prestigious peer-reviewed journal reflects both the importance of the data and the urgent need for an effective vaccine to slow the COVID-19 pandemic," Novavax's president of research and development, Gregory Glenn, said in a news release. After closing with a 2.1% decline at $102.90 in Wednesday's regular session, shares topped $107 in after-hours trading following release of the information. Novavax is one of at least 23 companies working on solutions to COVID-19 amid a global pandemic. Novavax shares have gained nearly 2,500% so far this year.
Reprinted from yahoofinance, the copyrights all reserved by the original author.
風險提示：本文所述僅代表作者個人觀點，不代表 Followme 的官方立場。Followme 不對內容的準確性、完整性或可靠性作出任何保證，對於基於該內容所採取的任何行為，不承擔任何責任，除非另有書面明確說明。
暫無評論，立馬搶沙發